Illumina

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. 

CEO
Jacob Thaysen
CEOJacob Thaysen
Employees
10,370
Employees10,370
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
10,370
Employees10,370

ILMN Key Statistics

Market cap
19.84B
Market cap19.84B
Price-Earnings ratio
29.04
Price-Earnings ratio29.04
Dividend yield
Dividend yield
Average volume
1.77M
Average volume1.77M
High today
$130.57
High today$130.57
Low today
$128.45
Low today$128.45
Open price
$128.45
Open price$128.45
Volume
1.96M
Volume1.96M
52 Week high
$153.06
52 Week high$153.06
52 Week low
$68.70
52 Week low$68.70

Stock Snapshot

The current Illumina(ILMN) stock price is $129.83, with a market capitalization of 19.84B. The stock trades at a price-to-earnings (P/E) ratio of 29.04.

During the trading session on 2025-11-26, Illumina(ILMN) shares reached a daily high of $130.57 and a low of $128.45. At a current price of $129.83, the stock is +1.1% higher than the low and still -0.6% under the high.

Trading volume for Illumina(ILMN) stock has reached 1.96M, versus its average volume of 1.77M.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

The stock's 52-week range extends from a low of $68.70 to a high of $153.06.

ILMN News

Simply Wall St 1d
How Will Analyst Reactions to ILMN’s Wolfe Conference Pitch Shape Confidence in Its Turnaround Plan?

Illumina, Inc. recently presented at the 7th Annual Wolfe Research Healthcare Conference in New York, where company leaders highlighted strategies to address ch...

How Will Analyst Reactions to ILMN’s Wolfe Conference Pitch Shape Confidence in Its Turnaround Plan?
Simply Wall St 3d
Illumina: A Fresh Look at Valuation as Protein Prep Gains Ground in Global Research Labs

Illumina (ILMN) just shared that its Protein Prep platform is now used by more than 40 customers in 16 locations worldwide, including renowned labs in Australia...

Illumina: A Fresh Look at Valuation as Protein Prep Gains Ground in Global Research Labs

Analyst ratings

48%

of 23 ratings
Buy
39.1%
Hold
47.8%
Sell
13%

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.